



Recombinant Vaccinia Virus (strain Western Reserve) Pseudokinase OPG198 (aa1-283, Full Length) (DAG-BY67)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview This item requires custom production and lead time is between 4-12 weeks. We can custom produce based on your specifications.

Species Vaccinia virus

Purity > 85% as determined by SDS-PAGE

Conjugate TBD

Applications Immunoassays

Format Liquid or Lyophilized powder

Size 1 mg

Storage Store at -20°C/-80°C upon receipt. Avoid repeated freeze-thaw cycles.

BACKGROUND

Introduction Smallpox was an infectious disease unique to humans, caused by either of two virus variants, Variola major and Variola minor. The disease is also known by the Latin names Variola or Variola vera, which is a derivative of the Latin varius, meaning "spotted", or varus, meaning "pimple". The term "smallpox" was first used in Britain in the 15th century to distinguish variola from the "great pox" (syphilis). The last naturally occurring case of smallpox (Variola minor) was diagnosed on 26 October 1977.

Keywords Vaccinia Virus Pseudokinase OPG198; B12R; Probable serine/threonine-protein kinase B12;

GENE INFORMATION

UniProt ID P24362

Function Pseudokinase that plays a role in viral DNA replication repression by activating the antiviral protein BANF1 and inhibiting the activity of host VRK1, a cellular modulator of BANF1.
